A Glypican-1-Targeted and Gemcitabine-Loaded Biocompatible Nanoplatform for Pancreatic Cancer Near-Infrared Fluorescence/Magnetic Resonance Multimodal Imaging and Therapy

Author(s):  
Wenli Qiu ◽  
Huifeng Zhang ◽  
Xiao Chen ◽  
Lina Song ◽  
Wenjing Cui ◽  
...  
2015 ◽  
Vol 42 (7) ◽  
pp. 1112-1118 ◽  
Author(s):  
Michaela Krohn ◽  
Sarah Ohrndorf ◽  
Stephanie G. Werner ◽  
Bernd Schicke ◽  
Gerd-Rüdiger Burmester ◽  
...  

Objective.Near-infrared fluorescence optical imaging (FOI) is a novel imaging technology in the detection and evaluation of different arthritides. FOI was validated in comparison to magnetic resonance imaging (MRI), greyscale ultrasonography (GSUS), and power Doppler ultrasonography (PDUS) in patients with early rheumatoid arthritis (RA).Methods.Hands of 31 patients with early RA were examined by FOI, MRI, and US. In each modality, synovitis of the wrist, metacarpophalangeal joints (MCP) 2–5, and proximal interphalangeal joints (PIP) 2–5 were scored on a 4-point scale (0–3). Sensitivity and specificity of FOI were analyzed in comparison to MRI and US as reference methods, differentiating between 3 phases of FOI enhancement (P1–3). Intraclass correlation coefficients (ICC) were calculated to evaluate the agreement of FOI with MRI and US.Results.A total of 279 joints (31 wrists, 124 MCP and 124 PIP joints) were evaluated. With MRI as the reference method, overall sensitivity/specificity of FOI was 0.81/0.00, 0.49/0.84, and 0.86/0.38 for wrist, MCP, and PIP joints, respectively. Under application of PDUS as reference, sensitivity was even higher, while specificity turned out to be low, except for MCP joints (0.88/0.15, 0.81/0.76, and 1.00/0.27, respectively). P2 appears to be the most sensitive FOI phase, while P1 showed the highest specificity. The best agreement of FOI was shown for PDUS, especially with regard to MCP and PIP joints (ICC of 0.57 and 0.53, respectively), while correlation with MRI was slightly lower.Conclusion.FOI remains an interesting diagnostic tool for patients with early RA, although this study revealed limitations concerning the detection of synovitis. Further research is needed to evaluate its full diagnostic potential in rheumatic diseases.


PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e90589 ◽  
Author(s):  
Kiran Vasudeva ◽  
Karl Andersen ◽  
Bree Zeyzus-Johns ◽  
T. Kevin Hitchens ◽  
Sravan Kumar Patel ◽  
...  

Nanomedicine ◽  
2019 ◽  
Vol 14 (17) ◽  
pp. 2339-2353 ◽  
Author(s):  
Wenli Qiu ◽  
Huifeng Zhang ◽  
Xiao Chen ◽  
Lina Song ◽  
Wenjing Cui ◽  
...  

Aim: Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. Materials & methods: This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer in vitro and in vivo. Results: Blood biochemical and histological analyses show that the in vivo toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both in vitro and in vivo studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. Conclusion: This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer.


Nanoscale ◽  
2014 ◽  
Vol 6 (15) ◽  
pp. 9264-9272 ◽  
Author(s):  
Gary Sitbon ◽  
Sophie Bouccara ◽  
Mariana Tasso ◽  
Aurélie Francois ◽  
Lina Bezdetnaya ◽  
...  

Cadmium-free quantum dots doped with Mn2+ions show promising results forin vivobimodal MRI and NIR fluorescence imaging.


Sign in / Sign up

Export Citation Format

Share Document